top of page
Research Article

      Abstract    

        

HOME

COMPARING CYSTATIN C AND KIM 1 TO CREATININE IN THE ASSESSMENT OF KIDNEY INJURY IN SICKLE CELL PATIENTS

 

Odewusi, O O, Oladokun T S, Nzelu, C A, Olaniyan O O, Obadire S O, Ogunyemi O M

​

Abstract: Sickle cell disease (SCD) is a group of blood genetic disorders resulting in an abnormality in the oxygen-carrying protein hemoglobin found in red blood cells. This study was carried out to compare Cystatin C and KIM 1 to creatinine in the assessment of kidney injury in sickle cell patients attending the Sickle cell Department of Federal Teaching Hospital Ido-Ekiti, Ekiti State Nigeria. A total of one hundred and four (104) individuals were recruited for this study comprising of 83 (79.81%) individuals who had history of sickle cell (subjects) and 21 (20.19%) individuals without sickle cell disease (control). Blood samples were collected from each subjects into plain bottle from which serum was separated and stored at -200C. Creatinine was determined spectrophotometrically using Jaffe’s method, while KIM 1 and Cystatin C levels were determined using ELISA. Statistical analysis was done using SPSS and significant difference was pegged at p<0.05. From the results obtained, the mean ± SD of KMI 1 (pg/mL) in crisis subjects, steady subjects and control was 1.58±0.84, 1.44±0.97 and 0.67±0.42, BMI (kg/m2) was 17.38±4.98, 21.42±2.20 and 22.21±1.77, Creatinine (mg/dl) was 2.45±1.80, 1.13±0.46 and 0.83±0.37, while Cystatin C (mmol/L) was 214.00±103.84, 194.12±132.96 and 55.89±17.21 respectively. Serum Cystatin C and KIM 1 levels were significantly higher (p<0.05) in both Steady and Crisis Subjects when compared with control. Serum creatinine levels was significantly higher (p<0.05) in crisis subjects compared with control. The research conclude that Kidney injury is a hallmark of Sickle cell Disease and that that Cystatin C and KIM 1 are better markers of Kidney Injury in Sickle Cell patients than creatinine.

​

KEYWORDS: Sickle Cell Disease, Renal Injury, Crisis, Steady State, KIM 1, Cystatin C

​

REFERENCES:​

  1. [1] National Health Service (NHS) Sickle cell anemia.Available at: www.nhs.uk/conditions/Sickle-cell-anemia/Pages/Introduction.aspx. Accessed May 10th 2023.

  2. [2] Ameh SJ, Tarfa FD, Ebeshi BU. Traditional herbal management of sickle cell anemia: lessons from Nigeria. Anemia 2012; 60: 7436-74369.

  3. [3] Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2015; 11,3: 161-171.

  4. [4] Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, Hay SI. Global epidemiology of sickle hemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. The Lancet, 2013; 381(9861), 142-151.

  5. [5] Nader E, Romana M, Connes P. The red blood cell—inflammation vicious circle in sickle cell disease. Frontiers in Immunology, 2020; 11, 454.

  6. [6] Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018; 68(2-3), 263-299.

  7. [7] Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC. Prevalence andpathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. New England Journal Medicine 1992; 326(14), 910–915.

  8. [8] Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's principles of internal medicine.

  9. [9] Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Kinney TR. Pain in sickle cell disease. Rates and risk factors. New England Journal Medicine 1991; 325: 11–16.

  10. [10] Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI. A new equation to estimate glomerular filtration rate.Annual Internatinal Medicine 2009; 150(9), 604–612.

  11. [11] Powars DR, Chan LS, Hiti A. Outcome of sickle cell anemia: A 4-decade observational study of 1056 patients. Medicine Baltimore 2005; 84(6), 363–376.

  12. [12] Barcelos RP, Stefanello ST, Mauriz JL, Gonzalez-Gallego J, Soares FA. Creatine and the Liver: Metabolism and Possible Interactions. Mini Reviews in Medicinal Chemistry 2016; 16,1: 12–18.

  13. [13] Samra M, Abcar AC. False estimates of elevated creatinine. Perm J. 2012; 16(2), 51-52.

  14. [14] Uemura O, Ushijima K, Nagai T. Reference serum cystatin C levels in children. Clinical Experiment Nephrology 2010; 14: 453–456

  15. [15] Schmitt F, Martinez F, Brillet G, Giatras I, Choukroun G, Girot R. Early glomerular dysfunction in patients with sickle cell anemia. American Journal Kidney Disease 1998; 32(2), 208–214.

  16. [16] Coresh J, Selvin E, Stevens LA. Prevalence of chronic kidney disease in the United States. Journal of American Medical Association, 2007; 298: 2038–2047.

  17. [17] Coresh J, Toto RD, Kirk KA, Whelton PR, Massry S, Jones C. Creatinine clearance as a measure of GFR in screenees for theAfrican-American study of kidney disease and hypertension pilot study. American Journal Kidney Disease 1998; 329: 32-42. 

  18. [18] Alvarez OA, Wright D, Lopez G, Zilleruelo G. Serum Cystatin C Is a Better Marker for Renal Function Than Serum Creatinine in Children with Sickle Cell Disease. Blood, 2005; 106: 3774-3776

  19. [19] Huang SH, Filler G, Yasin A, Lindsay RM. Cystatin C reduction ratio depends on normalized blood liters Processed and Fluid Removal during Hemodialysis. Clinical Journal American  Nephrology 2011; 6: 319–325.

  20. [20] Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell disease study of the risk factors. Archieved International Medicine 1987; 149: 1231–1234.

  21. [21] Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annual Review in Pathology 2019; 14: 263-292.

  22. [22] Chawla A, Sprinz PG, Welch J. Weight status of children with sickle cell disease. Pediatrics; 2013; 131:1168–1173.

  23. [23] Odetunde OI, Chinawa JM, Achigbu KI, Achigbu EO. Body mass index and other anthropometric variables in children with sickle cell anemia. Pakistan Journal of Medical Science 2016; 32(2), 341-346.

  24. [24] National Center for Biotechnology Information. PubChem Compound Summary for CID 588, creatinine. Retrieved May 10, 2023. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/creatinine.

  25. [25] Olawale OO, Adekanmbi AF, Sonuga AA, Sonuga OO, Akodu SO, Ogundeyi MM. Assessment of Renal Function Status in Steady-State Sickle Cell Anaemic Children Using Urine Human Neutrophil Gelatinase-Associated Lipocalin and Albumin:Creatinine Ratio. Medical Principle & Practice 2021; 30(6), 557-562.

  26. [26] Al-Naama LM, al-Sadoon EA, al-Sadoon TA. Levels of uric acid, urea and creatinine in Iraqi children with sickle cell disease. Journal of Pakistan Medical Association 2000; 50: 98-102

  27. [27] Silva-Junior GB, Vieira AP, Couto Bem AX, Alves MP, Meneses GC, Martins AM. Renal  tubular dysfunction in sickle cell disease. Kidney Blood Press Research 2013; 38: 1-10.

  28. [28] Pandey S, Sharma A, Dahia S, Shah V, Sharma V, Mishra RM. Biochemical indicator of sickle cell disease: Preliminary report from India. Indian Journal of Clinical Biochemistry 2012; 27: 191-195.

  29. [29] Gregory JK. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. American Journal of Haematology, 2009; 84 (9), 618-625

  30. [30] Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. American Journal of Kidney Disease 2002; 40(2), 221–226.

  31. [31] Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clinical Cardiology 2009; 32 (11), 644–648.

  32. [32] Tantawy AAG, Adly AAM, Ismail EAR, Abdelazeem M. Clinical Predictive Value of Cystatin C in Pediatric Sickle Cell Disease: A Marker of Disease Severity and Subclinical Cardiovascular Dysfunction. Clinical and Applied Thrombosis/Haemostasis 2017; 23(8), 1010-1017.

  33. [33] Pandey VK, Mani, Mazumdar P, Vidyapati, Prasad ML. Study of Serum Cystatin C and Serum Creatinine in Different Stages of Chronic Kidney Disease Patients. J Assoc Physicians India. 2022; 70(4), 11-12.

  34. [34] Song J, Yu J, Prayogo GW, Cao W, Wu Y, Jia Z, Zhang A. Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology. American Journal o Translation Research 2019; 11: 1219–1229.

  35. [35] Hoffmann D, Adler M, Vaidya VS, Rached E, Mulrane L, Gallagher WM, Callanan JJ, Gautier JC, Matheis K, Staedtler F, Dieterle F, Brandenburg A, Sposny A, Hewitt P, Ellinger-Ziegelbauer H, Bonventre JV, Dekant W, Mally A. Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicology Science 2010; 116: 8–22.

  36. [36] Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, Raman J, Jeevanandam V, O'Connor MF, Devarajan P, Bonventre JV, Murray PT. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clinical Journal of America Society of Nephrology 2010; 5: 2154–2165.

 To cite this article:

Odewusi, O O Oladokun T S Nzelu, C A, Olaniyan O O, Obadire S O, Ogunyemi O M. Comparing cystatin c and kim 1 to creatinine in the assessment of kidney injury in sickle cell patients. Int. J. Med. Lab. Res. 2023; 8,2:8-16. http://doi.org/10.35503/IJMLR.2023.8202

bottom of page